Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine plus reduced FLAG in older patients with high-risk or relapsed/refractory acute myeloid leukemia
ChiCTR1800016691Phase 4Not yet recruiting
- Sponsor
- Tianjin First Central Hospital
- Start
- Jul 2018
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of decitabine, fludarabine, cytarabine and filgrastim in acute myeloid leukemia (AML) (2 arms), sponsored by Tianjin First Central Hospital. Primary endpoints: Bone marrow examination, Blood routine examination and 1 more. Planned start Jul 2018; status: not yet recruiting.
02
Drugs
decitabinefludarabinecytarabinefilgrastim
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR1800016691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016691.